Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4287-4294

  Schiller, Joan H ^a   Bittner, Gerard ^b  

^a University of Wisconsin Health   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; SQUALAMINE;

ALKALINIZATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG TUMOR; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHOLESTANOLS; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033376890     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parker, S. L., Tong, T. Bolden, S. and Wingo, P. A. Cancer statistics, 1997. Ca. Cancer J. Clin., 47: 5-27, 1997.
2. Bunn, P. A., and Kelly, K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res., 5: 1087-1100, 1998.
3. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
4. Folkman, J., and Ingber, D. E. Angiostatic steroids. Ann. Surg., 206: 374-383, 1987.
5. Christian, M. C., Pluda, J. M., Ho, P. T., Arbuck, S. G., Murgo, A. J., and Sausville, E. A. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Semin. Oncol., 24: 219-240, 1997.
6. Harris, A. L. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res., 152: 341-352, 1998.
7. Eckhardt, S. G., and Pluda, J. M. Development of angiogenesis inhibitors for cancer therapy. Invest. New Drugs, 15: 1-3, 1997.
8. Williams, J. I. Squalamine - a new angiostatic steroid. In: B. Teicher, (ed.), Antiangiogenic Agents. Plymouth, MA: Humana Press, 1998.
9. Moore, K. S., Wehrli, S., Heinrich, R., Rogers, M., Forrest, J. N. J., McCrimmon, D., and Zasloff, M. Squalamine: an aminosterol antibiotic from the shark. Proc. Natl. Acad. Sci. USA, 90: 1354-1358, 1993.
10. Akhter, S., Nath, S. K., Tse, C. M., Williams, J., Zasloff, M., and Donowitz, M. Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Am. J. Physiol., 276: C136-144, 1999.
11. Sills, A. K., Williams, J. I., Tyler, B. M., Epstein, D. S., Sipos, E. P., Davis, J. D., McLane, M. P., Pitchford, S., Cheshire, K., Gannon, F. H., Kinney, W. A., Chao, T. L., Donowitz, M., Laterra, J., Zasloff, M., and Brem, H. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res., 58: 2784-2792, 1998.
12. Teicher, B. A., Williams, J. I., Takeuchi, H., Ara, G., Herbst, R. S., and Buxton, D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res., 18: 2567-2573, 1998.
13. Gonzalez, C., Marty, J., Weitman, S., VonHoff, D., and Williams, J. Squalamine enhances the antitumor activity of and carboplatin/paclitaxel in the chemoresistant MV-522 human lung tumor xenograft model. Proc. Am. Assoc. Cancer Res., 40: 591, 1999.
14. Schiller, J., and Bittner, G. Loss of tumorigenic phenotype in human bronchial epithelial cancer cell lines passaged in vitro but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an α5/β1 integrin/fibronectin interaction. Cancer Res., 55: 6215-6221, 1995.
15. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCulloch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., and Dirix, L. Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer, 32A: 2474-2484, 1996.
16. Sills, A., Epstein, D., and Sipos, E. Inhibition of tumor-induced neovascularization by squalamine, a novel angiogenesis inhibitor. 64th Ann. Mtg. of the Am. Assoc. of Neurological Surgeons. Minneapolis, MN, 1996.
17. Epstein, D., Sills, A., Brem, H., Collins, D., Williams, J., and Zasloff, M. Selective inhibition of VEGF-stimulated endothelial cells by squalamine. Am. Assoc. Neurological Surgeons, 1996.
18. Sakamoto, N., Tanaka, N. G., Tohgo, A., Osada, Y., and Ogawa, H. Inhibitory effects of heparin plus cortisone acetate on endothelial cell growth both in cultures and in tumor masses. J. Natl. Cancer Inst., 78: 581-585, 1987.
19. Gross, J., Azizkhan, R. G., Biswas, C., Bruns, R. R., Hsieh, D. S. T., and Folkman, J. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc. Natl. Acad. Sci. USA, 78: 1176-1180, 1981.
20. Mira-y-Lopez, R., Reiche, E., Stolfi, R. L., Martin, D. S., and Ossowski, L. Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma. Cancer Res., 45: 2270-2276, 1985.
21. Ashino-Fuse, H., Takano, Y., Oikawa, T., Shimamura, M., and Iwaguchi, T. Medroxyprogeterone acetate, and anti-cancer and antiangiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int. J. Cancer, 44: 859-864, 1989.
22. Wolff, J. E. A., Guerin, C., Laterra, J., Bressler, J., Indurti, R. R., Brem, H., and Godstein, G. W. Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res., 604: 79-85, 1993.
23. Pepper, M. S., Vassalli, J. D., Wilks, J. W., Schweigerer, L., Orci, L., and Montesano, R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell Biochem., 55: 419-434, 1994.
24. Yamamoto, T., Terada, N., Nishizawa, Y., and Petrow, V. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int. J. Cancer, 56: 393-399, 1994.
25. Blei, F., Wilson, E. L., Mignatti, P., and Rifkin, D. B. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell Physiol., 155: 568-578, 1993.
26. Ingber, D. E., Madri, J. A., and Folkman, J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology, 119: 1768- 1778, 1986.
27. Ingber, D., and Folkman, J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab. Invest., 59: 44-51, 1988.
28. Williams, J. I., Mangold, G., Zasloff, M., and von Hoff, D. D. Evaluation of the angiostatic squalamine as adjunctive chemotherapy for the MX-1 BAST cancer in a mouse model. Proc. Schilling Res. Conf. on Breast and Prostate Cancer. 1997.
29. 3 expression by squalamine obliterates advanced human prostate cancer: synergism with VEGF. Proc. Am. Assoc. Cancer Res., 1999:409.